{"id":"as-aq-carsucam","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1945534","moleculeType":"Small molecule","molecularWeight":"5841.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artemisinin derivatives generate reactive oxygen species that damage malaria parasite proteins and DNA, while amodiaquine acts as a quinoline antimalarial that interferes with parasite heme metabolism. The combination provides synergistic parasiticidal activity and helps prevent drug resistance through dual mechanisms of action.","oneSentence":"AS-AQ is a fixed-dose artemisinin-based combination antimalarial that kills malaria parasites through multiple mechanisms involving artemisinin and amodiaquine.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:24.530Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by other Plasmodium species susceptible to artemisinin-based combinations"}]},"trialDetails":[{"nctId":"NCT05343312","phase":"PHASE4","title":"In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique","status":"COMPLETED","sponsor":"Centro de Investigacao em Saude de Manhica","startDate":"2022-03-16","conditions":"Malaria","enrollment":870}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"AS-AQ (Carsucam)","genericName":"AS-AQ (Carsucam)","companyName":"Centro de Investigacao em Saude de Manhica","companyId":"centro-de-investigacao-em-saude-de-manhica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AS-AQ is a fixed-dose artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms of action. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria treatment in endemic regions (particularly sub-Saharan Africa).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}